Kodiak Sciences Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Victor Perlroth
- Full Time Employees
- 141
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1200 Page Mill Road Palo Alto CA United States of America 94304
- IPO Date
- Oct 4, 2018
- CIK
- 0001468748
- Website
- kodiak.com
- Similar Companies
- Business
- Kodiak Sciences Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of innovative treatments for prevalent retinal diseases. The company leverages its proprietary Antibody Biopolymer Conjugate (ABC®) platform to create long-acting therapies. Its lead investigational product, tarcocimab tedromer, an anti-vascular endothelial growth factor (VEGF) agent, has progressed through multiple Phase 3 clinical studies for various retinal vascular conditions, including diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The tarcocimab program was recently re-evaluated and is advancing with ongoing Phase 3 trials, GLOW2 for diabetic retinopathy and DAYBREAK for wet age-related macular degeneration, with topline results anticipated in 2026. Kodiak's pipeline also features KSI-501, a bispecific antibody biopolymer conjugate designed to inhibit both VEGF and interleukin-6 (IL-6) for retinal conditions with an inflammatory component, currently in a Phase 3 study for wet age-related macular degeneration, with topline data expected in 2026. Additionally, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF, has shown promising Phase 1b results for macular edema secondary to inflammation, and is now in two Phase 3 studies, PEAK and PINNACLE, with data expected in late 2026 and early 2027. In preclinical development, KSI-601 is a triplet inhibitor being explored for dry age-related macular degeneration. The company was established in 2009, initially as Oligasis, LLC, adopting the name Kodiak Sciences Inc. in September 2015, and operates from Palo Alto, California.
Company News
11 Stocks Most Likely to See a Short Squeeze Rally
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stock
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak Sciences Inc. (NASDAQ: KOD) Advances Zenkuda Toward Filing
Why Kodiak Sciences Skyrocketed Today
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study Results
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week High – Still a Buy?
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
Kodiak Sciences Inc. (NASDAQ:KOD) Receives $48.14 Consensus Target Price from Analysts
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Algert Global LLC Purchases 38,546 Shares of Kodiak Sciences Inc. $KOD